H.C. Wainwright lowered the firm’s price target on Lava Therapeutics to $6 from $9 and keeps a Buy rating on the shares post the Q2 report. Given the company’s strategic shift, the analyst removed LAVA-051 revenues from the financial model.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LVTX:
